Boston Scientific Continues Acquisition Streak With $1.75Bn Deal For Baylis’ Cardiology Products

The deal includes Baylis’ NRG and VersaCross transseptal access platforms which complement Boston Scientific’s catheter-based devices that require left-heart access.